NASDAQ:BIIB - Biogen Stock Price, News, & Analysis

Get Started

$227.06 -2.05 (-0.89 %)

(As of 05/27/2019 03:06 AM ET)

Previous Close$227.06

Today's Range$225.82 - $230.5150

52-Week Range$216.12 - $388.67

Volume1.79 million shs

Average Volume2.07 million shs

Market Capitalization$44.03 billion

P/E Ratio8.67

Dividend YieldN/A

Beta1.01

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:BIIB

Previous Symbol

CUSIP09062X10

CIK875045

Webhttp://www.biogen.com/

Phone617-679-2000

Debt

Debt-to-Equity Ratio0.43

Current Ratio2.84

Quick Ratio2.60

Price-To-Earnings

Trailing P/E Ratio8.67

Forward P/E Ratio7.68

P/E Growth1.04

Sales & Book Value

Annual Sales$13.45 billion

Price / Sales3.27

Cash Flow$30.9346 per share

Price / Cash Flow7.34

Book Value$71.29 per share

Price / Book3.19

Profitability

EPS (Most Recent Fiscal Year)$26.20

Net Income$4.43 billion

Net Margins33.79%

Return on Equity41.39%

Return on Assets21.63%

Miscellaneous

Employees7,800

Outstanding Shares193,893,000

Market Cap$44.03 billion

Next Earnings Date7/23/2019 (Estimated)

OptionableOptionable

Biogen (NASDAQ:BIIB) Frequently Asked Questions

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) issued its quarterly earnings results on Wednesday, April, 24th. The biotechnology company reported $6.98 EPS for the quarter, topping analysts' consensus estimates of $6.88 by $0.10. The biotechnology company had revenue of $3.49 billion for the quarter, compared to analysts' expectations of $3.38 billion. Biogen had a return on equity of 41.39% and a net margin of 33.79%. The business's revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.05 EPS. View Biogen's Earnings History.

When is Biogen's next earnings date?

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, July 23rd 2019. View Earnings Estimates for Biogen.

What price target have analysts set for BIIB?

32 equities research analysts have issued 1 year price targets for Biogen's stock. Their predictions range from $198.00 to $400.00. On average, they expect Biogen's stock price to reach $283.2308 in the next twelve months. This suggests a possible upside of 24.7% from the stock's current price. View Analyst Price Targets for Biogen.

What is the consensus analysts' recommendation for Biogen?

32 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 2 sell ratings, 24 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.

What are Wall Street analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:

1. Cantor Fitzgerald analysts commented, ": Reiterate Neutral rating and $250 price target. Yesterday Novartis (NVS, NC) announced FDA approval of its oral S1P1 Mayzent (siponimod) in secondary progressive multiple sclerosis (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome using a priority voucher. We think this broad label is somewhat unexpected given that the pivotal study and regulatory filings were for SPMS patients, and a negative headline for competitors such as Biogen and possibly Celgene CELG, OW). With competitive efficacy and a cleaner label vs. NVS’ first gen S1P1 Gilenya, we think the key question is if and how quickly Mayzent can take share in RRMS post launch in early 2Q." (3/27/2019)
2. HC Wainwright analysts commented, "Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (2/19/2019)
3. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call and BAN2401 data last week." (7/31/2018)

Has Biogen been receiving favorable news coverage?

News stories about BIIB stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biogen earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Biogen's key competitors?

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN) and Halozyme Therapeutics (HALO).

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Allergan (AGN), Intel (INTC) and Micron Technology (MU).

Who are Biogen's key executives?

Biogen's management team includes the folowing people:

Mr. Michel Vounatsos, CEO & Director (Age 57)
Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 54)
Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 62)
Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 50)
Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 53)

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.40%), Primecap Management Co. CA (7.52%), Clearbridge Investments LLC (4.43%), Wellington Management Group LLP (2.69%), AQR Capital Management LLC (2.18%) and Geode Capital Management LLC (1.57%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Which major investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Voya Investment Management LLC, Jackson Square Partners LLC, Janus Henderson Group PLC, OppenheimerFunds Inc., BlackRock Inc., Swedbank and PNC Financial Services Group Inc.. Company insiders that have sold Biogen company stock in the last year include Michael D Ehlers and Robert W Pangia. View Insider Buying and Selling for Biogen.

Which major investors are buying Biogen stock?

BIIB stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Boston Partners, Renaissance Technologies LLC, Geode Capital Management LLC, Parnassus Investments CA, SG Americas Securities LLC, MERIAN GLOBAL INVESTORS UK Ltd and Natixis. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $227.06.

How big of a company is Biogen?

Biogen has a market capitalization of $44.03 billion and generates $13.45 billion in revenue each year. The biotechnology company earns $4.43 billion in net income (profit) each year or $26.20 on an earnings per share basis. Biogen employs 7,800 workers across the globe.

What is Biogen's official website?

The official website for Biogen is http://www.biogen.com/.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]

MarketBeat Community Rating for Biogen (NASDAQ BIIB)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		1,521 (Vote Outperform)
Underperform Votes:		901 (Vote Underperform)
Total Votes:		2,422

MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 5/27/2019 by MarketBeat.com Staff

Featured Article: What is cost of equity?